UPDATED Apr 06, 2024
Well rounded companies, with acceptable leverage, projected to deliver an ROE north of 20% in three years.
Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | ||
---|---|---|---|---|---|---|---|---|---|---|
NATCOPHARM | ₹997.30 | 4.8% | 72.5% | ₹178.6b | ₹930.82 | PE14x | E14.3% | 1.0% |